Drug Profile
APL 1501
Alternative Names: APL-1301; APL-1501Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Asieris Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Urinary tract infections
- Preclinical Solid tumours
- No development reported Bladder cancer; Urogenital cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Bladder-cancer(Combination therapy, In volunteers) in Australia (PO, Tablet)
- 11 Sep 2023 Asieris plans a phase I trial in Bladder cancer (In Volunteers) in Australia (PO) (NCT06034015)
- 27 Jan 2023 Phase-I clinical trials in Urinary tract infections in Australia (PO) before January 2023 (Asieris Pharmaceuticals pipeline, January 2023)